Improvement in Cardiac Function With Enzyme Replacement Therapy in a Patient With Infantile-Onset Pompe Disease

REFERENCES

1. 1.↵
   1. Adam MP,
   2. Ardinger HH,
   3. Pagon RA,
   4. et al.

   1. Leslie N,
   2. Bailey L

   . Pompe disease. In: Adam MP, , Ardinger HH, , Pagon RA, ,et al., eds. GeneReviews^® [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2018. https://www.ncbi.nlm.nih.gov/books/NBK1261/. Published August 31, 2007. Updated May 11, 2017. Accessed August 8, 2018.
2. 2.↵
   1. Kishnani PS,
   2. Beckemeyer AA,
   3. Mendelsohn NJ

   . The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):1-7. doi: 10.1002/ajmg.c.31324.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Lloyd DF,
   2. Vara R,
   3. Mathur S

   . Cardiac manifestations of inherited metabolic disease in children. Pediatr Int. 2017 May;59(5):525-529. doi: 10.1111/ped.13272.

   OpenUrlCrossRef
4. 4.↵
   1. Chen M,
   2. Zhang L,
   3. Quan S

   . Enzyme replacement therapy for infantile-onset Pompe disease. Cochrane Database Syst Rev. 2017 Nov 20;11:CD011539. doi: 10.1002/14651858.CD011539.pub2.

   OpenUrlCrossRef
5. 5.↵
   1. Case LE,
   2. Bjartmar C,
   3. Morgan C,
   4. et al.

   Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Neuromuscul Disord. 2015 Apr;25(4):321-332. doi: 10.1016/j.nmd.2014.12.004.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. van Gelder CM,
   2. Poelman E,
   3. Plug I,
   4. et al.

   Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis. 2016 May;39(3):383-390. doi: 10.1007/s10545-015-9912-y.

   OpenUrlCrossRef
7. 7.↵
   1. Scriver CR,
   2. Beaudet A,
   3. Sly WS,
   4. Valle D

   1. Hirschhorn R,
   2. Reuser AJ

   . Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, , Beaudet A, , Sly WS, , Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:3389-3420.
8. 8.↵
   1. Lim JA,
   2. Zare H,
   3. Puertollano R,
   4. Raben N

   . Atg5^flox-derived autophagy-deficient model of Pompe disease: does it tell the whole story? Mol Ther Methods Clin Dev. 2017 Sep 22;7:11-14. doi: 10.1016/j.omtm.2017.08.002.

   OpenUrlCrossRef
9. 9.↵
   1. Nascimbeni AC,
   2. Fanin M,
   3. Masiero E,
   4. Angelini C,
   5. Sandri M

   . The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII). Cell Death Differ. 2012 Oct;19(10):1698-1708. doi: 10.1038/cdd.2012.52.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Levine JC,
    2. Kishnani PS,
    3. Chen YT,
    4. Herlong JR,
    5. Li JS

    . Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol. 2008 Nov;29(6):1033-1042. doi: 10.1007/s00246-008-9267-3.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Desai AK,
    2. Walters CK,
    3. Cope HL,
    4. Kazi ZB,
    5. DeArmey SM,
    6. Kishnani PS

    . Enzyme replacement therapy with alglucosidase alfa in Pompe disease: clinical experience with rate escalation. Mol Genet Metab. 2018 Feb;123(2):92-96. doi: 10.1016/j.ymgme.2017.12.435.

    OpenUrlCrossRef
12. 12.↵
    1. Hordeaux J,
    2. Dubreil L,
    3. Robveille C,
    4. et al.

    Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. Acta Neuropathol Commun. 2017 Sep 6;5(1):66. doi: 10.1186/s40478-017-0464-2.

    OpenUrlCrossRef
13. 13.↵
    1. Broomfield A,
    2. Fletcher J,
    3. Davison J,
    4. et al.

    Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy. J Inherit Metab Dis. 2016 Mar;39(2):261-271. doi: 10.1007/s10545-015-9898-5.

    OpenUrlCrossRef
14. 14.↵
    1. Matsuoka T,
    2. Miwa Y,
    3. Tajika M,
    4. et al.

    Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state. Mol Genet Metab Rep. 2016 Nov 18;9:98-105.

    OpenUrl
15. 15.↵
    1. Avula S,
    2. Nguyen TM,
    3. Marble M,
    4. Lilje C

    . Cardiac response to enzyme replacement therapy in infantile Pompe disease with severe hypertrophic cardiomyopathy. Echocardiography. 2017 Apr;34(4):621-624. doi: 10.1111/echo.13490.

    OpenUrlCrossRef